Last reviewed · How we verify
Varicella Virus Vaccine Live
This live attenuated vaccine stimulates the immune system to recognize and protect against varicella-zoster virus by inducing both cellular and humoral immunity.
This live attenuated vaccine stimulates the immune system to recognize and protect against varicella-zoster virus by inducing both cellular and humoral immunity. Used for Prevention of varicella (chickenpox) in susceptible individuals, Post-exposure prophylaxis of varicella in non-immune individuals.
At a glance
| Generic name | Varicella Virus Vaccine Live |
|---|---|
| Also known as | Varicella vaccine, VARIVAX®, Varivax |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened (attenuated) form of varicella-zoster virus that replicates in the body at low levels, triggering T-cell and B-cell responses without causing severe disease. This immune priming allows the body to rapidly recognize and neutralize wild-type virus upon natural exposure, preventing chickenpox infection or reducing disease severity.
Approved indications
- Prevention of varicella (chickenpox) in susceptible individuals
- Post-exposure prophylaxis of varicella in non-immune individuals
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Varicella-like rash (vaccine strain)
- Myalgia
Key clinical trials
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varicella Virus Vaccine Live CI brief — competitive landscape report
- Varicella Virus Vaccine Live updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI